8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

Key Takeaways Explain This Topic AI

Absolute/urgent indications for emergent renal replacement therapy in the ICU are summarized by the "AEIOU" mnemonic: refractory severe Acidosis (pH < 7.15), life-threatening refractory Electrolyte derangements (hyperkalemia with ECG changes), dialyzable toxic Ingestions (SLIME), diuretic-refractory pulmonary Overload, and overt Uremic complications (pericarditis, encephalopathy, bleeding diathesis).

Landmark multicenter randomized controlled trials (AKIKI, IDEAL-ICU, STARRT-AKI) consistently show that early or accelerated initiation of RRT in critically ill patients with Stage 2 or 3 AKI without urgent AEIOU criteria does not reduce 60- or 90-day mortality compared to a watchful waiting strategy.

Accelerated RRT initiation inflicts tangible clinical harm: the STARRT-AKI trial showed higher rates of adverse events (hypotension, hypophosphatemia, vascular access trauma) and a statistically significant increase in persistent chronic dialysis dependence at 90 days (10.4% vs 6.0%).

A watchful waiting approach with active medical management allows 38% to 49% of patients with severe AKI to spontaneously recover renal function without ever requiring an invasive dialysis catheter or extracorporeal circuit.

Clinical trials (VA/NIH ATN and ANZICS RENAL) establish that the optimal delivered CRRT effluent dose is 20 to 25 mL/kg/h; high-intensity dosing (35 to 40 mL/kg/h) provides zero survival benefit and exacerbates electrolyte depletion and drug clearance.

Last updated: October 2026

Urgent Indications for Renal Replacement Therapy: The "AEIOU" Framework

In critically ill patients with acute kidney injury, the decision to initiate renal replacement therapy (RRT) begins with identifying absolute, life-threatening clinical emergencies. When present, these conditions mandate emergent dialytic intervention regardless of KDIGO stage or urine output trajectory. The classical "AEIOU" mnemonic structures this urgent evaluation:

Loading diagram...

1. Acidosis (Metabolic)

Severe, uncompensated metabolic acidosis with an arterial pH < 7.15 to 7.20 \text{pH} < 7.15\text{ to }7.20 pH < 7.15 to 7.20 and serum bicarbonate < 10 to 12 mEq/L < 10\text{ to }12\text{ mEq/L} < 10 to 12 mEq/L that is refractory to conservative medical therapy (or where exogenous sodium bicarbonate infusion is contraindicated due to severe hypernatremia, hypocalcemia, or volume overload). Acidemia below 7.15 severely impairs myocardial contractility, induces peripheral vasodilation, desensitizes vascular smooth muscle to exogenous catecholamines/vasopressors, and triggers malignant ventricular arrhythmias.

2. Electrolytes (Hyperkalemia)

Severe, refractory hyperkalemia ( serum potassium > 6.5 mEq/L > 6.5\text{ mEq/L} > 6.5 mEq/L ) accompanied by electrocardiographic signs of membrane instability (peaked T waves, PR prolongation, loss of P waves, QRS widening, or sine-wave patterns) that fails to stabilize following aggressive pharmacotherapy:

• Intravenous calcium gluconate or calcium chloride (myocardial membrane stabilization);
• Intravenous regular insulin plus 50 % 50\% 50% dextrose (intracellular potassium shift);
• Inhaled beta-2 agonists (albuterol 10 to 20 mg 10\text{ to }20\text{ mg} 10 to 20 mg nebulized);

Gastrointestinal potassium binders (sodium zirconium cyclosilicate [Lokelma] or patiromer).

Severe refractory hypermagnesemia ( > 8 to 10 mg/dL > 8\text{ to }10\text{ mg/dL} > 8 to 10 mg/dL ) with flaccid paralysis or respiratory depression, or severe refractory hypercalcemic crisis in the setting of oliguric renal failure also represent dialytic indications.

3. Ingestions (Dialyzable Toxins: "SLIME")

Emergent extracorporeal removal is indicated for specific low-molecular-weight, water-soluble, low-volume-of-distribution toxins summarized by the SLIME mnemonic:

S — Salicylates : Serum level > 90 to 100 mg/dL > 90\text{ to }100\text{ mg/dL} > 90 to 100 mg/dL ( > 80 mg/dL > 80\text{ mg/dL} > 80 mg/dL in renal failure) or presence of severe neurological toxicity, pulmonary edema, or refractory acid-base decompensation;

L — Lithium (EXTRIP 2015): Recommended if kidney function is impaired and [ Li + ] > 4.0 mEq/L [\text{Li}^+] > 4.0\text{ mEq/L} [ Li + ] > 4.0 mEq/L , or with decreased consciousness, seizures, or life-threatening dysrhythmias at any level; suggested if [ Li + ] > 5.0 mEq/L [\text{Li}^+] > 5.0\text{ mEq/L} [ Li + ] > 5.0 mEq/L , with significant confusion, or if the expected time to reach < 1.0 mEq/L < 1.0\text{ mEq/L} < 1.0 mEq/L exceeds 36 hours;

I — Isopropanol : When accompanied by severe hemorrhagic gastritis or refractory hypotension (though conservative support is often attempted first);

M — Methanol (EXTRIP 2015): Coma, seizures, new visual deficits, pH ≤ 7.15 \le 7.15 ≤ 7.15 , anion gap > 24 > 24 > 24 , or persistent acidosis despite treatment; or a methanol level > 70 mg/dL > 70\text{ mg/dL} > 70 mg/dL on fomepizole ( > 60 > 60 > 60 on ethanol, > 50 > 50 > 50 without an alcohol dehydrogenase blocker);

E — Ethylene Glycol (EXTRIP 2023): Anion gap > 27 mmol/L > 27\text{ mmol/L} > 27 mmol/L (suggested at 23-27), coma, seizures, or AKI; on fomepizole, ECTR is suggested for an EG level > 50 mmol/L > 50\text{ mmol/L} > 50 mmol/L ( > 310 mg/dL > 310\text{ mg/dL} > 310 mg/dL ) or osmolal gap > 50 > 50 > 50 ; a glycolate concentration above 12 mmol/L 12\text{ mmol/L} 12 mmol/L (suggested at 8-12) is an alternative trigger where it can be measured;

Additional dialyzable toxins : Theophylline, toxic overdoses of metformin presenting with profound metformin-associated lactic acidosis (MALA), carbamazepine, and valproic acid.

4. Overload (Fluid)

Diuretic-refractory hypervolemia manifest as worsening hypoxemic respiratory failure (flash pulmonary edema) or severe systemic venous congestion in an oliguric or anuric patient. In patients unresponsive to maximal loop diuresis ( > 160 to 240 mg > 160\text{ to }240\text{ mg} > 160 to 240 mg IV furosemide equivalent combined with a thiazide such as metolazone or IV chlorothiazide), extracorporeal ultrafiltration is life-saving.

5. Uremia (End-Organ Manifestations)

Overt uremic organ dysfunction:

Uremic Pericarditis : Manifest as retrosternal pleuritic chest pain and a scratchy, pathognomonic triphasic friction rub, frequently with a serosanguinous pericardial effusion.

Caution

In patients with uremic pericarditis, systemic anticoagulation (e.g., heparin) is strictly contraindicated during dialysis circuits due to the high risk of transforming serofibrinous inflammation into acute hemorrhagic cardiac tamponade.

Uremic Encephalopathy : Cognitive slowing, asterixis (flapping tremor), multifocal myoclonus, seizures, and progressive coma.

Uremic Bleeding Diathesis : Impaired primary hemostasis resulting from uremic toxins (such as guanidinosuccinic acid) interfering with platelet glycoprotein IIb/IIIa receptors and von Willebrand factor binding. Clinically reversed by desmopressin (DDAVP 0.3 μ g/kg 0.3\ \mu\text{g/kg} 0.3 μ g/kg IV), cryoprecipitate, and emergent dialytic clearance.

The Timing Controversy: Accelerated vs. Watchful Waiting Strategies

While urgent "AEIOU" indications demand immediate intervention, the management of patients with severe AKI (KDIGO Stage 2 or 3) who lack immediate life-threatening complications historically generated fierce debate.

The Pro-Early Hypothesis : Proponents argued that preemptive, accelerated initiation of RRT would prevent the lethal systemic sequelae of uremia, eliminate toxic inflammatory mediators, maintain tight fluid balance, and avert emergency dialysis under unstable conditions.

The Pro-Delayed (Watchful Waiting) Hypothesis : Opponents highlighted that renal replacement therapy is inherently invasive and hazardous. Catheter insertion risks pneumothorax, arterial puncture, and catheter-related bloodstream infections (CRBSI). Dialytic circuits induce hypotension, activate systemic leukocytes, strip away essential trace elements and antibiotic levels, and cause fluctuations in renal perfusion that retard endogenous tubular regeneration. Crucially, many patients with Stage 2 or 3 AKI spontaneously recover renal function if given adequate time and supportive medical management.

Landmark Randomized Controlled Trials

Four landmark multicenter randomized trials definitively resolved this debate over the past decade:

Loading diagram...

1. The AKIKI Trial (NEJM 2016)

Design : Multicenter randomized trial in 31 French ICUs enrolling 620 patients with KDIGO Stage 3 AKI receiving invasive mechanical ventilation, vasopressor therapy, or both.

Strategies :

Early Strategy : RRT initiated immediately within 6 hours of documenting KDIGO Stage 3 AKI.

Delayed Strategy : RRT withheld until urgent indications developed (hyperkalemia > 6.0 mEq/L > 6.0\text{ mEq/L} > 6.0 mEq/L , pH < 7.15 < 7.15 < 7.15 , acute pulmonary edema, or BUN > 112 mg/dL > 112\text{ mg/dL} > 112 mg/dL ) or persistent oliguria/anuria exceeded 72 hours.

Results :

60-day all-cause mortality was virtually identical: 48.5 % 48.5\% 48.5% in the early group vs. 49.7 % 49.7\% 49.7% in the delayed group ( p = 0.79 p = 0.79 p = 0.79 ).

49 % 49\% 49% of patients in the delayed group spontaneously recovered renal function and never received RRT .

The early initiation group suffered significantly higher rates of catheter-related bloodstream infections ( 10 % 10\% 10% vs. 5 % 5\% 5% , p = 0.03 p = 0.03 p = 0.03 ).

2. The IDEAL-ICU Trial (NEJM 2018)

Design : Multicenter French trial enrolling 488 patients with septic shock and severe AKI in the RIFLE "Failure" stage.

Strategies : Early initiation (within 12 hours of Failure stage) vs. Delayed initiation (deferred for 48 hours unless AEIOU indications arose).

Results : The trial was terminated early for futility at the planned interim analysis. 90-day mortality showed no significant difference ( 58 % 58\% 58% early vs. 54 % 54\% 54% delayed , p = 0.38 p = 0.38 p = 0.38 ). In the delayed group, 38 % 38\% 38% of patients never required RRT .

3. The STARRT-AKI Trial (NEJM 2020)

Design : The definitive international, multicenter trial across 168 centers in 15 countries, randomizing 3,019 critically ill patients (2,927 in the modified intention-to-treat analysis) with KDIGO Stage 2 or 3 AKI.

Strategies :

Accelerated Strategy : RRT initiated within 12 hours of meeting eligibility (median time to initiation: 6.1 hours ).

Standard (Watchful Waiting) Strategy : RRT withheld until urgent indications developed (severe hyperkalemia, severe acidosis, volume overload) or persistent renal failure lasted ≥ 72 hours \ge 72\text{ hours} ≥ 72 hours (median time to initiation in those who received RRT: 31.1 hours ).

Results :

90-Day All-Cause Mortality : Identical between groups: 43.9 % 43.9\% 43.9% (643/1,465) in the accelerated group vs. 43.7 % 43.7\% 43.7% (639/1,462) in the standard group (relative risk 1.00; 95 % 95\% 95% CI 0.93 to 1.09; p = 0.92 p = 0.92 p = 0.92 ).

RRT Avoidance : In the standard group, 38 % 38\% 38% of patients never received RRT due to spontaneous renal recovery or death before intervention.

Adverse Events : The accelerated group experienced significantly higher rates of adverse events ( 23.0 % 23.0\% 23.0% vs. 16.5 % 16.5\% 16.5% , p < 0.001 p < 0.001 p < 0.001 ), driven by severe hypotension and hypophosphatemia.

Persistent Dialysis Dependence : Among 90-day survivors, the rate of chronic dialysis dependence was significantly higher in the accelerated group ( 10.4 % 10.4\% 10.4% vs. 6.0 % 6.0\% 6.0% ; RR 1.74, 95% CI 1.24 to 2.43) . Premature catheter insertion, circuit hypotension, and dialytic removal of physiological regulatory molecules impaired long-term parenchymal renal recovery.

4. The AKIKI-2 Trial (Lancet 2021)

Design : Tested whether postponing RRT initiation even further than the standard delayed strategy provided incremental benefit or caused harm. Compared a "delayed" strategy (dialysis when oliguria > 72 hours > 72\text{ hours} > 72 hours or BUN reaches 112 mg/dL 112\text{ mg/dL} 112 mg/dL ) with an "ultra-delayed" strategy (withholding until BUN reached > 140 mg/dL > 140\text{ mg/dL} > 140 mg/dL or urgent AEIOU criteria).

Results : The primary outcome, RRT-free days at day 28, did not differ (median 12 vs. 10 days). The more-delayed strategy offered no benefit and had a signal of harm: 60-day mortality was numerically higher (about 55% vs. 44%), reaching significance only in an adjusted analysis. The practical lesson is that once oliguria exceeds 72 hours or BUN exceeds 112 mg/dL, postponing RRT further gains nothing .

Comparison Table of Landmark RRT Timing Trials

Trial (Year) Patient Population Sample Size ( n n n ) Early / Accelerated Arm Delayed / Standard Arm Key Clinical Findings

AKIKI (NEJM 2016) Stage 3 AKI on mechanical ventilation or vasopressors 620 Immediate initiation ( < 6 hr < 6\text{ hr} < 6 hr ) Withheld until AEIOU criteria or oliguria > 72 hr > 72\text{ hr} > 72 hr 60-day mortality identical (48.5% vs 49.7%); 49% avoided RRT ; early arm had more bacteremia

IDEAL-ICU (NEJM 2018) Septic shock with severe AKI (RIFLE-Failure) 488 Initiation within 12 hr of Failure stage Deferred for 48 hr unless AEIOU indications arose Stopped for futility; 90-day mortality 58% vs 54%; 38% avoided RRT

STARRT-AKI (NEJM 2020) KDIGO Stage 2 or 3 AKI in ICU 3,019 Accelerated initiation (median 6.1 hr) Standard watchful waiting (deferred until AEIOU or ≥ 72 hr \ge 72\text{ hr} ≥ 72 hr ) 90-day mortality identical (43.9% vs 43.7%); 38% avoided RRT ; accelerated arm had higher 90-day dialysis dependence (10.4% vs 6.0%)

AKIKI-2 (Lancet 2021) Stage 3 AKI in ICU 278 Standard delayed (oliguria > 72 hr > 72\text{ hr} > 72 hr or BUN > 112 mg/dL > 112\text{ mg/dL} > 112 mg/dL ) Ultra-delayed (withheld until BUN > 140 mg/dL > 140\text{ mg/dL} > 140 mg/dL or severe AEIOU) No difference in RRT-free days (primary); adjusted mortality signal of harm with further delay

Clinical Consensus and Pragmatic Management

Synthesizing this robust trial evidence establishes a standard ICU clinical pathway:

Screen for Immediate Emergent Indications : Immediately initiate RRT if refractory "AEIOU" emergencies are present.

If No Emergent Criteria (Stage 2/3 AKI) : Adopt a watchful waiting strategy with aggressive medical support:

Optimize systemic hemodynamics and renal perfusion pressure (target MAP ≥ 65 mmHg \ge 65\text{ mmHg} ≥ 65 mmHg , or MAP 75 to 85 mmHg in chronic hypertensive patients);

• Administer a furosemide stress test or trial of loop diuretics to assess tubular responsiveness;
• Restrict unnecessary maintenance fluids to prevent progressive fluid accumulation;
• Administer potassium binders and sodium bicarbonate for mild-to-moderate acid-base/electrolyte abnormalities;

Perform serial clinical examinations, blood gas analyses, and electrolyte panels every 6 to 12 hours.

Initiate RRT When : Refractory AEIOU criteria emerge, progressive hypervolemia compromises respiratory mechanics, or significant oliguria persists past 48 to 72 hours with escalating azotemia (BUN approaching 100 to 112 mg/dL).

Effluent Dose Target: Evidence from ATN and RENAL Trials

Once the decision to initiate CRRT is made, the clinician must prescribe the dialytic intensity, quantified as the effluent flow rate per unit body weight ( Q effluent Q_{\text{effluent}} Q effluent ​ , in mL/kg/h \text{mL/kg/h} mL/kg/h ) .

Landmark Intensity Trials

Two landmark multicenter randomized trials evaluated whether "intensive" or high-dose CRRT improved patient outcomes compared to standard dosing:

The VA/NIH Acute Renal Failure Trial Network (ATN) Study (NEJM 2008) :

Randomized 1,124 critically ill patients with AKI and multiorgan failure to intensive therapy (CVVHDF at 35 mL/kg/h 35\text{ mL/kg/h} 35 mL/kg/h or daily intermittent hemodialysis) versus standard therapy (CVVHDF at 20 mL/kg/h 20\text{ mL/kg/h} 20 mL/kg/h or thrice-weekly intermittent hemodialysis).

Results : 60-day mortality was identical: 53.6 % 53.6\% 53.6% intensive vs. 51.5 % 51.5\% 51.5% standard ( p = 0.47 p = 0.47 p = 0.47 ). No differences were seen in renal recovery or ICU length of stay. Intensive therapy significantly increased hypotensive episodes and hypophosphatemia.

The ANZICS RENAL Trial (NEJM 2009) :

Randomized 1,508 critically ill patients in Australia and New Zealand to high-dose CVVHDF ( 40 mL/kg/h 40\text{ mL/kg/h} 40 mL/kg/h ) versus standard-dose CVVHDF ( 25 mL/kg/h 25\text{ mL/kg/h} 25 mL/kg/h ) .

Results : 90-day mortality was identical: 44.7 % 44.7\% 44.7% in the high-dose group vs. 44.7 % 44.7\% 44.7% in the standard-dose group ( p = 0.99 p = 0.99 p = 0.99 ). High-dose CRRT caused significantly higher rates of severe hypophosphatemia ( 65 % 65\% 65% vs. 54 % 54\% 54% ) and increased the clearance of essential trace minerals and therapeutic antibiotics.

Clinical Standard and the "Prescribed vs. Delivered" Gap

Based on the ATN and RENAL trials, the KDIGO guidelines recommend a delivered effluent dose of 20 to 25 mL/kg/h 20\text{ to }25\text{ mL/kg/h} 20 to 25 mL/kg/h for CRRT in acute kidney injury.

Tip

In clinical practice, the delivered dose is frequently 15 to 25 % 15\text{ to }25\% 15 to 25% lower than the prescribed dose due to inevitable circuit interruptions: circuit clotting, diagnostic imaging (CT scans), operating room procedures, central line changes, and filter replacements. Therefore, clinicians should routinely prescribe an effluent dose of 25 to 30 mL/kg/h 25\text{ to }30\text{ mL/kg/h} 25 to 30 mL/kg/h to ensure that the actual delivered dose achieves the evidence-based target of 20 to 25 mL/kg/h 20\text{ to }25\text{ mL/kg/h} 20 to 25 mL/kg/h .